Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Gastric Cancer | Research

Toll-like receptor 9 (-1237 T/C, -1486 T/C) and the risk of gastric cancer: a meta-analysis of genetic association studies

Authors: Yap Zi Qyi, Htar Htar Aung, Saint-Nway Aye, Wong Siew Tung, Cho Naing

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Gastric cancer has a complex aetiology including genetic factors. Individual case-control studies of toll like receptor (TLR) 9 (-1237 T/C, -1486 T/C) polymorphisms in the gastric cancer risk were available, and they showed variation in the findings. Therefore, we performed a meta-analysis to synthesize the evidence on the association between polymorphisms of TLR 9 (-1237 T/C, -1486 T/C) and the risk of gastric cancer using data from eligible studies.

Methods

This study followed the PRISMA 2020 Checklist. Studies were searched in health-related databases. The methodological quality of studies was evaluated with the use of Newcastle-Ottawa Scale criteria. The summary odds ratio (OR) and its 95% confidence interval (CI) were used to determine the strength of association between each polymorphism and the risk of gastric cancer using five genetic models. Stratification was done by ethnic groups. For the robustness of the analysis, a leave-one-out meta-analysis was performed.

Results

Eight case-control studies with 3,644 participants (1914 cases, 1730 controls) were conducted across six countries. Half of the studies were conducted in China. In the NOS methodological quality assessment, only three studies received a high-quality rating (i.e., a score of ≥ 7). TLR 9 (-1486 T/C) polymorphism and the risk of gastric cancer were assessed in six studies, four of Asian ethnicity and two of non-Asian. Under the dominant model, only in the Asian ethnic group showed a marginally and significantly increased risk of gastric cancer (overall: OR = 1.22, 95%CI = 0.90–1.67, I2 = 56%; Asian: OR = 1.24, 95%CI = 1.00-1.54, I2 = 0%, non-Asian: OR = 1.25, 95%CI = 0.38–4.09, I2 = 89%). Under the recessive model in the absence of heterogeneity, only the Asian group had a significantly higher risk of developing gastric cancer (overall: OR = 1.4, 95% CI = 0.74–2.64, I2 = 85%; Asian: OR: 1.41, 95% CI = 1.07–1.86, I2 = 0%, non-Asian: OR = 1.18, 95% CI = 0.12–11.76, I2 = 97%). Under the heterozygous model, there was no significant association with the risk of gastric cancer overall or among any ethnic subgroup. Under the homozygous model in the absence of heterogeneity, only the Asian group had a significantly higher risk of gastric cancer (overall, OR = 1.47, 95% CI = 0.76–2.86, I2 = 82%; Asian: OR = 1.54, 95% CI = 1.13–2.1, I2 = 0%; non-Asian: OR = 1.19, 95% CI = 0.1-14.33, I2 = 96%). Under the allele model, a significantly increased risk of gastric cancer was observed only in the Asian group (overall: OR = 1.23, 95% CI = 0.89–1.71, I2 = 84%; Asian: OR = 1.22, 95% CI = 1.05–1.41, I2 = 0%; non-Asian: OR = 1.24, 95% CI = 0.34–4.59, I2 = 97%). Four studies investigated the association between TLR 9 (-1237 T/C) polymorphism and the risk of developing gastric cancer. Under any of the five genetic models, there was no association between TLR 9 (-1237 T/C) and the development of gastric cancer in overall or in any ethnic subgroup. Sensitivity analysis revealed that the effect was unstable. With a small number of studies with a small number of participants, we addressed the issue of insufficient power for drawing conclusions.

Conclusions

The findings suggested that TLR9 (-1486 T/C) may play a role in the risk of gastric cancer specific to the Asian ethnic group. To substantiate the findings on the association between these two polymorphisms (TLR9 -1237 T/C, -1486 T/C) and the risk of gastric cancer, future well-designed case-control studies with a sufficient number of participants in multi-ethnic groups are recommended.
Appendix
Available only for authorised users
Literature
1.
go back to reference Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20:338–49.CrossRefPubMed Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20:338–49.CrossRefPubMed
2.
go back to reference Ernst PB, Gold BD. The Disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal Ulcer and gastric cancer. Annu Rev Microbiol. 2000;54:615–40.CrossRefPubMed Ernst PB, Gold BD. The Disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal Ulcer and gastric cancer. Annu Rev Microbiol. 2000;54:615–40.CrossRefPubMed
5.
go back to reference Liu S, Wang X, Shi Y, Han L, Zhao Z, Zhao C, et al. Toll-like receptor gene polymorphisms and susceptibility to Epstein-Barr virus-associated and -negative gastric carcinoma in Northern China. Saudi J Gastroenterol. 2015;21(2):95–103.CrossRefPubMedPubMedCentral Liu S, Wang X, Shi Y, Han L, Zhao Z, Zhao C, et al. Toll-like receptor gene polymorphisms and susceptibility to Epstein-Barr virus-associated and -negative gastric carcinoma in Northern China. Saudi J Gastroenterol. 2015;21(2):95–103.CrossRefPubMedPubMedCentral
6.
go back to reference Patel MK, Trombly MI, Kurt-Jones EA. Innate immune responses to Helicobacter pylori Infection: an overview. Methods Mol Biol. 2012;921:205–7.CrossRefPubMed Patel MK, Trombly MI, Kurt-Jones EA. Innate immune responses to Helicobacter pylori Infection: an overview. Methods Mol Biol. 2012;921:205–7.CrossRefPubMed
7.
go back to reference Uno K, Kato K, Shimosegawa T. Novel role of toll-like receptors in Helicobacter pylori - induced gastric malignancy. World J Gastroenterol. 2014;20:5244–51.CrossRefPubMedPubMedCentral Uno K, Kato K, Shimosegawa T. Novel role of toll-like receptors in Helicobacter pylori - induced gastric malignancy. World J Gastroenterol. 2014;20:5244–51.CrossRefPubMedPubMedCentral
8.
10.
go back to reference Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801.CrossRefPubMed Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801.CrossRefPubMed
11.
go back to reference Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA. 2001;98:9237–42.CrossRefPubMedPubMedCentral Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA. 2001;98:9237–42.CrossRefPubMedPubMedCentral
12.
go back to reference Hornef MW, Bogdan C. The role of epithelial toll-like receptor expression in host defense and microbial tolerance. J Endotoxin Res. 2005;11:124–8.CrossRefPubMed Hornef MW, Bogdan C. The role of epithelial toll-like receptor expression in host defense and microbial tolerance. J Endotoxin Res. 2005;11:124–8.CrossRefPubMed
13.
go back to reference Kabisch R, Mejias-Luque R, Gerhard M, Prinz C. Involvement of toll-like receptors on Helicobacter pylori-induced immunity. PLoS ONE. 2014;9(8):e104804.CrossRefPubMedPubMedCentral Kabisch R, Mejias-Luque R, Gerhard M, Prinz C. Involvement of toll-like receptors on Helicobacter pylori-induced immunity. PLoS ONE. 2014;9(8):e104804.CrossRefPubMedPubMedCentral
14.
go back to reference Hold GL, Rabkin CS, Gammon MD, Berry SH, Smith MG, Lissowska J, et al. CD14-159 C/T and TLR 9-1237 T/C polymorphisms are not associated with gastric cancer risk in caucasian populations. Eur J Cancer Prev. 2009;18(2):117–9.CrossRefPubMedPubMedCentral Hold GL, Rabkin CS, Gammon MD, Berry SH, Smith MG, Lissowska J, et al. CD14-159 C/T and TLR 9-1237 T/C polymorphisms are not associated with gastric cancer risk in caucasian populations. Eur J Cancer Prev. 2009;18(2):117–9.CrossRefPubMedPubMedCentral
15.
go back to reference Mosteller F, Colditz GA. Understanding research synthesis (meta-analysis). Annu Rev Public Health. 1996;17:1–23.CrossRefPubMed Mosteller F, Colditz GA. Understanding research synthesis (meta-analysis). Annu Rev Public Health. 1996;17:1–23.CrossRefPubMed
16.
go back to reference Trikalinos TA, Salanti G, Zintzaras E, Ioannidis JP. Meta-analysis methods. Adv Genet. 2008;60:311–34.CrossRefPubMed Trikalinos TA, Salanti G, Zintzaras E, Ioannidis JP. Meta-analysis methods. Adv Genet. 2008;60:311–34.CrossRefPubMed
18.
go back to reference Yuan Y, Hunt RH. Systematic reviews: the good, the bad, and the ugly. Am J Gastroenterol. 2009;104:1086–92.CrossRefPubMed Yuan Y, Hunt RH. Systematic reviews: the good, the bad, and the ugly. Am J Gastroenterol. 2009;104:1086–92.CrossRefPubMed
19.
20.
go back to reference Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy- Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13:840–8.CrossRefPubMed Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy- Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13:840–8.CrossRefPubMed
21.
go back to reference Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed
22.
23.
go back to reference Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–6.CrossRefPubMed Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–6.CrossRefPubMed
24.
go back to reference Deeks JJ, Higgins JPT, Altman DG,Chapter 10: Analysing data and undertaking meta-analyses. In:, Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Deeks JJ, Higgins JPT, Altman DG,Chapter 10: Analysing data and undertaking meta-analyses. In:, Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022.
25.
go back to reference CDC (Centers for Dises Control) and Prevention). : Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion. Asian, Native Hawaiian and Pacific Islander People and Commercial Tobacco: Health Disparities and Ways to Advance Health Equity. June 22, 2022. CDC (Centers for Dises Control) and Prevention). : Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion. Asian, Native Hawaiian and Pacific Islander People and Commercial Tobacco: Health Disparities and Ways to Advance Health Equity. June 22, 2022.
26.
go back to reference Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046–55.CrossRefPubMed Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046–55.CrossRefPubMed
27.
go back to reference Wang X, Xue L, Yang Y, Xu L, Zhang G. TLR9 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. PLoS ONE. 2013;8(6):e65731.CrossRefPubMedPubMedCentral Wang X, Xue L, Yang Y, Xu L, Zhang G. TLR9 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. PLoS ONE. 2013;8(6):e65731.CrossRefPubMedPubMedCentral
28.
go back to reference Susi MD, Lourenço Caroline M, Rasmussen LT, Payão SLM, Rossi AFT, Silva AE, de Oliveira-Cucolo JG. Toll-like receptor 9 polymorphisms and Helicobacter pylori influence gene expression and risk of gastric carcinogenesis in the Brazilian population. World J Gastrointest Oncol. 2019;11(11):998–1010.CrossRefPubMedPubMedCentral Susi MD, Lourenço Caroline M, Rasmussen LT, Payão SLM, Rossi AFT, Silva AE, de Oliveira-Cucolo JG. Toll-like receptor 9 polymorphisms and Helicobacter pylori influence gene expression and risk of gastric carcinogenesis in the Brazilian population. World J Gastrointest Oncol. 2019;11(11):998–1010.CrossRefPubMedPubMedCentral
29.
go back to reference De Re V, Repetto O, De Zorzi M, Casarotto M, Tedeschi M, Giuffrida P, et al. Polymorphism in toll-like receptors and Helicobacter Pylori motility in autoimmune atrophic gastritis and gastric cancer. Cancers (Basel). 2019;11(5):648.CrossRefPubMed De Re V, Repetto O, De Zorzi M, Casarotto M, Tedeschi M, Giuffrida P, et al. Polymorphism in toll-like receptors and Helicobacter Pylori motility in autoimmune atrophic gastritis and gastric cancer. Cancers (Basel). 2019;11(5):648.CrossRefPubMed
30.
go back to reference Gao F, Qin J, Wei X, Tian X, Dong W, Dang T, et al. Polymorphisms of TLR9 gene are associated with a decreased risk of H. Pylori Infection in a Chinese population. Transl Cancer Res. 2020;9(2):683–9.CrossRefPubMedPubMedCentral Gao F, Qin J, Wei X, Tian X, Dong W, Dang T, et al. Polymorphisms of TLR9 gene are associated with a decreased risk of H. Pylori Infection in a Chinese population. Transl Cancer Res. 2020;9(2):683–9.CrossRefPubMedPubMedCentral
30.
go back to reference Ding L, Chakrabarti J, Sheriff S, Li Q, Thi Hong HN, Sontz RA, et al. Toll-like receptor 9 pathway mediates Schlafen+-MDSC polarization during helicobacter-induced gastric meta plasias. Gastroenterology. 2022;163(2):411–425e4.CrossRefPubMed Ding L, Chakrabarti J, Sheriff S, Li Q, Thi Hong HN, Sontz RA, et al. Toll-like receptor 9 pathway mediates Schlafen+-MDSC polarization during helicobacter-induced gastric meta plasias. Gastroenterology. 2022;163(2):411–425e4.CrossRefPubMed
31.
go back to reference Sultan AM, Shenouda R, Sultan AM, Shehta A, Nabiel Y. The relation between host TLR9 -1486T/C, rs187084 gene polymorphisms and Helicobacter pylori cagA, sodB, hsp60, and vacA virulence genes among gastric cancer patients. Pol J Microbiol. 2022;71(1):35–42.CrossRefPubMedPubMedCentral Sultan AM, Shenouda R, Sultan AM, Shehta A, Nabiel Y. The relation between host TLR9 -1486T/C, rs187084 gene polymorphisms and Helicobacter pylori cagA, sodB, hsp60, and vacA virulence genes among gastric cancer patients. Pol J Microbiol. 2022;71(1):35–42.CrossRefPubMedPubMedCentral
32.
go back to reference Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96(6):434–42.CrossRefPubMedPubMedCentral Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96(6):434–42.CrossRefPubMedPubMedCentral
33.
go back to reference Wang J. Estimating genotyping errors from genotype and reconstructed pedigree data. Methods Ecol Evol. 2018;9:109–20.CrossRef Wang J. Estimating genotyping errors from genotype and reconstructed pedigree data. Methods Ecol Evol. 2018;9:109–20.CrossRef
Metadata
Title
Toll-like receptor 9 (-1237 T/C, -1486 T/C) and the risk of gastric cancer: a meta-analysis of genetic association studies
Authors
Yap Zi Qyi
Htar Htar Aung
Saint-Nway Aye
Wong Siew Tung
Cho Naing
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11509-7

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine